Using Drosophila to identify therapeutic targets for Neurodegenerative Disease MCBU June 2012 Larry...
-
Upload
laila-converse -
Category
Documents
-
view
227 -
download
5
Transcript of Using Drosophila to identify therapeutic targets for Neurodegenerative Disease MCBU June 2012 Larry...
![Page 1: Using Drosophila to identify therapeutic targets for Neurodegenerative Disease MCBU June 2012 Larry Marsh; Laszlo Bodai Dept of Developmental and Cell.](https://reader036.fdocuments.net/reader036/viewer/2022062421/56649d835503460f94a68fae/html5/thumbnails/1.jpg)
Using Drosophila to identify Using Drosophila to identify therapeutic targets for therapeutic targets for
Neurodegenerative Disease Neurodegenerative Disease MCBU June 2012 MCBU June 2012
Larry Marsh; Laszlo BodaiLarry Marsh; Laszlo BodaiDept of Developmental and Cell BiologyDept of Developmental and Cell Biology
German EncisoGerman EncisoDept of MathematicsDept of Mathematics
Alex IhlerAlex IhlerICS Information and Computer ScienceICS Information and Computer Science
![Page 2: Using Drosophila to identify therapeutic targets for Neurodegenerative Disease MCBU June 2012 Larry Marsh; Laszlo Bodai Dept of Developmental and Cell.](https://reader036.fdocuments.net/reader036/viewer/2022062421/56649d835503460f94a68fae/html5/thumbnails/2.jpg)
OutlineOutline Gene expression is regulated by Gene expression is regulated by
chromatin marks such as acHistonechromatin marks such as acHistone Neurodegenerative diseases cause Neurodegenerative diseases cause
abnormal gene expression patterns and abnormal gene expression patterns and altered Histone acetylation patternsaltered Histone acetylation patterns
Can we correlate particular chromatin Can we correlate particular chromatin modifying proteins with particular gene modifying proteins with particular gene sets and can we identify the most sets and can we identify the most therapeutically attractive?therapeutically attractive?
System: Human disease genes System: Human disease genes expressed in Drosophilaexpressed in Drosophila
![Page 3: Using Drosophila to identify therapeutic targets for Neurodegenerative Disease MCBU June 2012 Larry Marsh; Laszlo Bodai Dept of Developmental and Cell.](https://reader036.fdocuments.net/reader036/viewer/2022062421/56649d835503460f94a68fae/html5/thumbnails/3.jpg)
HuntingtonHuntington’’s disease is a s disease is a dominantdominant, , late onset neurodegenerative diseaselate onset neurodegenerative disease
NormalNormalbrainbrain
HDHDbrainbrain
![Page 4: Using Drosophila to identify therapeutic targets for Neurodegenerative Disease MCBU June 2012 Larry Marsh; Laszlo Bodai Dept of Developmental and Cell.](https://reader036.fdocuments.net/reader036/viewer/2022062421/56649d835503460f94a68fae/html5/thumbnails/4.jpg)
HD is one of several HD is one of several Protein MisfoldingProtein Misfolding diseases diseases
CAG - polyQ (glutamine)CAG - polyQ (glutamine)HD (Huntingtin -Htt) HD (Huntingtin -Htt) Marsh, Benzer, JacksonMarsh, Benzer, Jackson
DRPLA (Atrophin-1) DRPLA (Atrophin-1) SCA-1 (Ataxin-1) SCA-1 (Ataxin-1) Fernandez-Funez..Botas Fernandez-Funez..Botas
SCA-2 (Ataxin-2) SCA-2 (Ataxin-2) SCA-3 (Ataxin-3) SCA-3 (Ataxin-3) Warrick…BoniniWarrick…Bonini
SBMA (Androgen Receptor) SBMA (Androgen Receptor) Takeyama..KatoTakeyama..Kato
SCA-6 (CaSCA-6 (Ca2+2+channel)*channel)*SCA-7 (Ataxin-7)SCA-7 (Ataxin-7)
5’ 3’
ParkinsonParkinson’’ss Feany, BoniniFeany, Bonini
AlzheimerAlzheimer’’s/Tauopathiess/Tauopathies Jackson; Suzuki, Feany , WittmanJackson; Suzuki, Feany , Wittman
![Page 5: Using Drosophila to identify therapeutic targets for Neurodegenerative Disease MCBU June 2012 Larry Marsh; Laszlo Bodai Dept of Developmental and Cell.](https://reader036.fdocuments.net/reader036/viewer/2022062421/56649d835503460f94a68fae/html5/thumbnails/5.jpg)
Protein MisfoldingProtein Misfolding diseases - a common theme diseases - a common theme
Alpha synuclein Alpha synuclein ‘‘Lewy BodiesLewy Bodies’’ in in ParkinsonParkinson’’ss
ß amyloid plaques in Alzheimerß amyloid plaques in Alzheimer’’ss
Neurofibrillary tangles of Tau protein inside Neurofibrillary tangles of Tau protein inside nerve-cells of the Alzheimernerve-cells of the Alzheimer’’s brains brainPoly Q inclusion in SCA3, HD and Poly Q inclusion in SCA3, HD and
other polyQ diseasesother polyQ diseases
![Page 6: Using Drosophila to identify therapeutic targets for Neurodegenerative Disease MCBU June 2012 Larry Marsh; Laszlo Bodai Dept of Developmental and Cell.](https://reader036.fdocuments.net/reader036/viewer/2022062421/56649d835503460f94a68fae/html5/thumbnails/6.jpg)
Expansion of PolyQ above a Expansion of PolyQ above a threshold causes diseasethreshold causes disease
Normal Htt = 6-34 QsNormal Htt = 6-34 Qs Adult onset = 37-40 QsAdult onset = 37-40 Qs
≥ ≥41-121 always disease41-121 always disease
≥ ≥ 70 Qs = juvenile onset 70 Qs = juvenile onset e.g. ≤ 21yearse.g. ≤ 21years
Number of CAG Repeat UnitsNumber of CAG Repeat Units
00 1010 2020 3030 4040 5050 6060 7070 8080 9090 100100 12012000
2020
4040
6060
8080
Ag
e at
N
euro
log
ic O
nse
tA
ge
at
Neu
rolo
gic
On
set
![Page 7: Using Drosophila to identify therapeutic targets for Neurodegenerative Disease MCBU June 2012 Larry Marsh; Laszlo Bodai Dept of Developmental and Cell.](https://reader036.fdocuments.net/reader036/viewer/2022062421/56649d835503460f94a68fae/html5/thumbnails/7.jpg)
Can weCan we‘‘humanizehumanize’’ a fly a fly to mimic the neurodegeneration to mimic the neurodegeneration
seen in manseen in manWill this speed target Will this speed target
identification for testing in identification for testing in mammals?mammals?
Modeling HD in DrosophilaModeling HD in Drosophila
![Page 8: Using Drosophila to identify therapeutic targets for Neurodegenerative Disease MCBU June 2012 Larry Marsh; Laszlo Bodai Dept of Developmental and Cell.](https://reader036.fdocuments.net/reader036/viewer/2022062421/56649d835503460f94a68fae/html5/thumbnails/8.jpg)
Drosophila can be engineered to Drosophila can be engineered to express foreign genes express foreign genes
anywhere, anytimeanywhere, anytime
tissue tissue specific specific
promoterspromoters
Q22Q22 UAS Q22Q22
Q108Q108 UAS
Q93 Htt exon 1Q93 Htt exon 1 UAS Q93Q93
Q108Q108
Gal4 TATAElavUAS
UAS
X
Htt polyQUAS
Gal4 TATAElavUAS
UAS
Htt polyQUAS
![Page 9: Using Drosophila to identify therapeutic targets for Neurodegenerative Disease MCBU June 2012 Larry Marsh; Laszlo Bodai Dept of Developmental and Cell.](https://reader036.fdocuments.net/reader036/viewer/2022062421/56649d835503460f94a68fae/html5/thumbnails/9.jpg)
normal HD
Hu
ma
n b
rain
Httex1Q93Httex1Q93day 12day 12
polyQ108polyQ108normalnormal
Fly
eye
Fly
eye
HuntingtonHuntington’’s disease can be mimicked s disease can be mimicked in fliesin flies
Compound eye SEM section pseudopupilCompound eye SEM section pseudopupil
Normal eye structureNormal eye structure
Photoreceptor neurons degeneratePhotoreceptor neurons degenerate
![Page 10: Using Drosophila to identify therapeutic targets for Neurodegenerative Disease MCBU June 2012 Larry Marsh; Laszlo Bodai Dept of Developmental and Cell.](https://reader036.fdocuments.net/reader036/viewer/2022062421/56649d835503460f94a68fae/html5/thumbnails/10.jpg)
Expression of human Htt in flies causes Expression of human Htt in flies causes widespread degenerationwidespread degeneration
Renderings by L.Chang; A.Chaing, NTHURenderings by L.Chang; A.Chaing, NTHU
Mushroom body of adult fly brainMushroom body of adult fly brain
KCBKCB
OK107>Httex1Q93;GFPOK107>Httex1Q93;GFP
’’behindbehind
’’
KCBKCB
OK107>GFPOK107>GFP
![Page 11: Using Drosophila to identify therapeutic targets for Neurodegenerative Disease MCBU June 2012 Larry Marsh; Laszlo Bodai Dept of Developmental and Cell.](https://reader036.fdocuments.net/reader036/viewer/2022062421/56649d835503460f94a68fae/html5/thumbnails/11.jpg)
elav>Htt exon1Q93elav>Htt exon1Q93
Days post eclosionDays post eclosion
44
55
66
77
11 55 77 1212wtwtph
oto
rece
pto
r n
euro
ns
ph
oto
rece
pto
r n
euro
ns
wtwt
day 1 day 3 day 6Q48Q48
Degeneration is progressiveDegeneration is progressive
![Page 12: Using Drosophila to identify therapeutic targets for Neurodegenerative Disease MCBU June 2012 Larry Marsh; Laszlo Bodai Dept of Developmental and Cell.](https://reader036.fdocuments.net/reader036/viewer/2022062421/56649d835503460f94a68fae/html5/thumbnails/12.jpg)
The role of chromatin modifications The role of chromatin modifications on transcriptional dysregulation on transcriptional dysregulation
and disease pathogenesis and disease pathogenesis in vivoin vivo
![Page 13: Using Drosophila to identify therapeutic targets for Neurodegenerative Disease MCBU June 2012 Larry Marsh; Laszlo Bodai Dept of Developmental and Cell.](https://reader036.fdocuments.net/reader036/viewer/2022062421/56649d835503460f94a68fae/html5/thumbnails/13.jpg)
Transcription is dysregulated in HD patientsTranscription is dysregulated in HD patients
![Page 14: Using Drosophila to identify therapeutic targets for Neurodegenerative Disease MCBU June 2012 Larry Marsh; Laszlo Bodai Dept of Developmental and Cell.](https://reader036.fdocuments.net/reader036/viewer/2022062421/56649d835503460f94a68fae/html5/thumbnails/14.jpg)
CHD1CHD1SAGASAGA
HAT complexHAT complex
Hum H3 n-ARTHum H3 n-ARTKKQTARQTARKKSTGGSTGGKK……44 99
K4K4 K9K9K4K41,2me1,2me
K4K43me3me
Ash1, Rtf1,Trr, Trx?Ash1, Rtf1,Trr, Trx?
Su(var)3-3?Su(var)3-3?
Lid/JARID1CLid/JARID1C
K9K9acac
K9K9meme
HATs,CBPHATs,CBP
Ash1,Egg,G9a,
Ash1,Egg,G9a,Su(var)3-9
Su(var)3-9??
Cg8165,15835,33182?
Cg8165,15835,33182?
Sin3A,Rpd3, Sir2
Sin3A,Rpd3, Sir2
MeMeMeMe
HP1HP1
Factor bindingFactor bindingActivationActivation
Transcription is regulated by modifying histones.Transcription is regulated by modifying histones.e.g. H3K4;9e.g. H3K4;9
AcAcAcAc
1414
![Page 15: Using Drosophila to identify therapeutic targets for Neurodegenerative Disease MCBU June 2012 Larry Marsh; Laszlo Bodai Dept of Developmental and Cell.](https://reader036.fdocuments.net/reader036/viewer/2022062421/56649d835503460f94a68fae/html5/thumbnails/15.jpg)
Does acetylation homeostasis contribute to Does acetylation homeostasis contribute to pathology pathology in vivoin vivo??
HHH
Ac-CoAHDACs
onon
HATse.g CBP
Pol II complex
Ac-CoA
HDACs
HH
offoffH
Pol II complex
HATs
polyQCan we target Can we target
HDACs?HDACs?
normalnormal
HDHD
Steffan et al. Steffan et al. NatureNature. 413:739 (2001).. 413:739 (2001).
![Page 16: Using Drosophila to identify therapeutic targets for Neurodegenerative Disease MCBU June 2012 Larry Marsh; Laszlo Bodai Dept of Developmental and Cell.](https://reader036.fdocuments.net/reader036/viewer/2022062421/56649d835503460f94a68fae/html5/thumbnails/16.jpg)
Genetic reduction of HDAC activity Genetic reduction of HDAC activity slows degenerationslows degeneration
Sin3A is a general cofactor for class I & II HDACsSin3A is a general cofactor for class I & II HDACs
Phot
orep
tor n
euro
nsPh
otor
epto
r neu
rons
HDHD
HD HD &&
Sin3A+/-Sin3A+/-
5.05.0
5.45.4
5.85.8
6.26.2
6.66.6
7.07.0
CyOCyO Sin3A+/-Sin3A+/-
NormalNormal
![Page 17: Using Drosophila to identify therapeutic targets for Neurodegenerative Disease MCBU June 2012 Larry Marsh; Laszlo Bodai Dept of Developmental and Cell.](https://reader036.fdocuments.net/reader036/viewer/2022062421/56649d835503460f94a68fae/html5/thumbnails/17.jpg)
Pharmacologic inhibition of HDACs slows Pharmacologic inhibition of HDACs slows progressiveprogressive degeneration degeneration
% o
mm
atid
ia%
om
mat
idia
0
10
20
30
40
50
1 2 3 4 5 6 7
Q48 Q48+inhibitorQ48+inhibitor@ 6 days
Q48 + butyrate 100 mMQ48 Q48
Day 1 Day 6 Day 6
wt
Steffan et al. Steffan et al. NatureNature. 413:739 (2001).. 413:739 (2001).
![Page 18: Using Drosophila to identify therapeutic targets for Neurodegenerative Disease MCBU June 2012 Larry Marsh; Laszlo Bodai Dept of Developmental and Cell.](https://reader036.fdocuments.net/reader036/viewer/2022062421/56649d835503460f94a68fae/html5/thumbnails/18.jpg)
Normal-treated-sickNormal-treated-sick
![Page 19: Using Drosophila to identify therapeutic targets for Neurodegenerative Disease MCBU June 2012 Larry Marsh; Laszlo Bodai Dept of Developmental and Cell.](https://reader036.fdocuments.net/reader036/viewer/2022062421/56649d835503460f94a68fae/html5/thumbnails/19.jpg)
Does HDAC therapy Does HDAC therapy translate to mammals?translate to mammals?
![Page 20: Using Drosophila to identify therapeutic targets for Neurodegenerative Disease MCBU June 2012 Larry Marsh; Laszlo Bodai Dept of Developmental and Cell.](https://reader036.fdocuments.net/reader036/viewer/2022062421/56649d835503460f94a68fae/html5/thumbnails/20.jpg)
All in a day’s work, I suppose
HELP!
R6/2 + SAHAR6/2 + SAHAP = 0.0001
00
200200
300300
100100
44 88 1010 1212
Tim
e o
n r
od
(s
ec
s)T
ime
on
ro
d (
se
cs)
Age/weeksAge/weeks
P = 0.0006
R6/2R6/2
+/++/+
+/++/+ HD -R6/2HD -R6/2
HDAC inhibitors slow progressive HDAC inhibitors slow progressive degeneration in micedegeneration in mice
Hockly, E. et al. Hockly, E. et al. PNASPNAS. 100, 2014 (2003).. 100, 2014 (2003).
Normal butyrate in R6/2 R6/2[HD]Normal butyrate in R6/2 R6/2[HD]
Ferrante,. et al. Ferrante,. et al. J NeurosciJ Neurosci 23, 9418 (2003). 23, 9418 (2003).
![Page 21: Using Drosophila to identify therapeutic targets for Neurodegenerative Disease MCBU June 2012 Larry Marsh; Laszlo Bodai Dept of Developmental and Cell.](https://reader036.fdocuments.net/reader036/viewer/2022062421/56649d835503460f94a68fae/html5/thumbnails/21.jpg)
But which HDACs are relevant?But which HDACs are relevant?
TypeType
Catalytic gene products Catalytic gene products
Co-repressorsCo-repressorsDrosophilaDrosophila humanhuman
Class IClass I
Usually Usually ubiquitous & ubiquitous & nuclearnuclear
Rpd3Rpd3 HDAC1, HDAC2HDAC1, HDAC2 Sin3ASin3A
Mi-2/NurdMi-2/Nurd
Bin1Bin1HDAC3HDAC3 HDAC3, (8)HDAC3, (8)
HDAC11HDAC11 HDAC11 HDAC11 class 4class 4
Class IIClass IIa; ba; b
Tissue specific & Tissue specific & shuttleshuttle
HDAC4HDAC4 HDAC4, 5, 7, 9HDAC4, 5, 7, 9 Sin3A Sin3A
NcoRNcoR
SMRTSMRTHDAC6HDAC6 HDAC6, (10)HDAC6, (10)
Class IIIClass III
sirtuinssirtuinsNAD dependentNAD dependent
Sir2Sir2 sirt1sirt1
Sirt2Sirt2 sirt2sirt2
![Page 22: Using Drosophila to identify therapeutic targets for Neurodegenerative Disease MCBU June 2012 Larry Marsh; Laszlo Bodai Dept of Developmental and Cell.](https://reader036.fdocuments.net/reader036/viewer/2022062421/56649d835503460f94a68fae/html5/thumbnails/22.jpg)
Rpd3 is most effective at relieving pathology Rpd3 is most effective at relieving pathology among the class I, II, IV HDACsamong the class I, II, IV HDACs
elav>Httex193Q photoreceptor degeneration - day 7elav>Httex193Q photoreceptor degeneration - day 7
Class IClass I Class IVClass IVClass IIClass II
Ph
oto
rec
ep
tor
#P
ho
tore
ce
pto
r #
4.44.4
4.64.6
4.84.8
55
5.25.2
5.45.4
CtlCtl Rpd3Rpd3--
++HDAC11HDAC11--
++CtlCtl
4.44.4
4.64.6
4.84.8
55
5.25.2
5.45.4
4.44.4
4.64.6
4.84.8
55
5.25.2
5.45.4
HDAC6HDAC6--
++CtlCtlHDAC3HDAC3--
++CtlCtl
4.4
4.8
5.2
5.6
6
6.4
4.4
4.8
5.2
5.6
6
6.4
CtlCtl HDAC4HDAC4--
++
![Page 23: Using Drosophila to identify therapeutic targets for Neurodegenerative Disease MCBU June 2012 Larry Marsh; Laszlo Bodai Dept of Developmental and Cell.](https://reader036.fdocuments.net/reader036/viewer/2022062421/56649d835503460f94a68fae/html5/thumbnails/23.jpg)
Genetic reduction of Sir2 improves pathologyGenetic reduction of Sir2 improves pathology
sir2 LOFsir2 LOF
Sir2 -/+Sir2 -/+
sir2 GOFsir2 GOF
Sir2 EP(oe)Sir2 EP(oe)
surv
ival
surv
ival
% o
f c
on
tro
l
0
10
20
30
40
50
60
0
10
20
30
40
50
60
Phot
orep
tors
Phot
orep
tors
4.4
4.6
4.8
5
5.2
5.4
4.5
4.7
4.9
5.1
5.3
5.5
CtlCtlCtlCtlPallos et al HMG 2008Pallos et al HMG 2008
![Page 24: Using Drosophila to identify therapeutic targets for Neurodegenerative Disease MCBU June 2012 Larry Marsh; Laszlo Bodai Dept of Developmental and Cell.](https://reader036.fdocuments.net/reader036/viewer/2022062421/56649d835503460f94a68fae/html5/thumbnails/24.jpg)
44
4.54.5
55
5.55.5
0 µM0 µM 0.1 µM0.1 µM 1.0 µM1.0 µM 10 µM10 µM 100mM100mMButyrateButyrateSEL (uM)SEL (uM)
Phot
orec
epto
r neu
rons
Phot
orec
epto
r neu
rons
Selisistat (SEL), an indole based inhibitor of Sir2 Selisistat (SEL), an indole based inhibitor of Sir2 exhibits dose dependent rescue of retinal exhibits dose dependent rescue of retinal
neuronsneurons
![Page 25: Using Drosophila to identify therapeutic targets for Neurodegenerative Disease MCBU June 2012 Larry Marsh; Laszlo Bodai Dept of Developmental and Cell.](https://reader036.fdocuments.net/reader036/viewer/2022062421/56649d835503460f94a68fae/html5/thumbnails/25.jpg)
R6/2 Veh
R6/2 Selisistat 5 mg/kg
Ventricular enlargement
0
100000
200000
300000
400000
500000
600000
*
arb
itra
ry u
nit
sStriatal degeneration is suppressed by Striatal degeneration is suppressed by
Selistat in R6/2 miceSelistat in R6/2 mice
Siena BiotechSiena Biotech
Veh 5mg/kgVeh 5mg/kg
![Page 26: Using Drosophila to identify therapeutic targets for Neurodegenerative Disease MCBU June 2012 Larry Marsh; Laszlo Bodai Dept of Developmental and Cell.](https://reader036.fdocuments.net/reader036/viewer/2022062421/56649d835503460f94a68fae/html5/thumbnails/26.jpg)
Pathology is sensitive toPathology is sensitive toRpd3 and Sir2Rpd3 and Sir2
TypeType Catalytic gene products Catalytic gene products RescueRescue
Drosophila (5+)Drosophila (5+) Human (11+)Human (11+)
Class IClass I
Usually ubiquitous Usually ubiquitous & nuclear& nuclear
Rpd3Rpd3 HDAC1, HDAC2HDAC1, HDAC2 YYHDAC3HDAC3 HDAC3, (8)HDAC3, (8) --HDAC11HDAC11 HDAC11HDAC11 --
Class IIClass IITissue specific & Tissue specific & shuttleshuttle
HDAC4HDAC4 HDAC4, 5, 7, 9HDAC4, 5, 7, 9 --HDAC6HDAC6 HDAC6, (10)HDAC6, (10) --
Class IIIClass IIINAD dependentNAD dependent
Sir2Sir2 sirt1sirt1 YYsirt2sirt2 sirt2sirt2 Y Y
Pallos et al HMG 2008Pallos et al HMG 2008
![Page 27: Using Drosophila to identify therapeutic targets for Neurodegenerative Disease MCBU June 2012 Larry Marsh; Laszlo Bodai Dept of Developmental and Cell.](https://reader036.fdocuments.net/reader036/viewer/2022062421/56649d835503460f94a68fae/html5/thumbnails/27.jpg)
Mining the dataMining the data
1- Can one identify disease relevant HDAC’s by finding those that influence the 1- Can one identify disease relevant HDAC’s by finding those that influence the expression of a set of genes that are also altered by polyglutamine expression of a set of genes that are also altered by polyglutamine overexpression? overexpression?
2- Are there common sets of dysregulated genes seen in the different polyQ 2- Are there common sets of dysregulated genes seen in the different polyQ disease models (and possibly in other disease models like ALZ and PD)? disease models (and possibly in other disease models like ALZ and PD)?
3- Are there HDAC’s that exhibit a chromatin binding pattern that overlaps with the 3- Are there HDAC’s that exhibit a chromatin binding pattern that overlaps with the genomic location of the genes dysregulated upon polyglutamine expression? This genomic location of the genes dysregulated upon polyglutamine expression? This question is based on the observation that altered genes do not appear to be question is based on the observation that altered genes do not appear to be randomly distributed on the chromosome .randomly distributed on the chromosome .
4- Finally, some studies suggest that the genome can be described in terms of 5-9 4- Finally, some studies suggest that the genome can be described in terms of 5-9 different chromatin domain types (e.g. housekeeping genes vs developmentally different chromatin domain types (e.g. housekeeping genes vs developmentally regulated vs heterochromatin etc). For example, Filion et al describe 5 domains regulated vs heterochromatin etc). For example, Filion et al describe 5 domains based on binding data of transcription factors while Kharchenko et al , describe 9 based on binding data of transcription factors while Kharchenko et al , describe 9 domains based on chromatin modification marks. Can the dysregulated genes in domains based on chromatin modification marks. Can the dysregulated genes in Htt challenged animals be found to correlate with a specific chromatin domain Htt challenged animals be found to correlate with a specific chromatin domain identified by previous studies? identified by previous studies?
![Page 28: Using Drosophila to identify therapeutic targets for Neurodegenerative Disease MCBU June 2012 Larry Marsh; Laszlo Bodai Dept of Developmental and Cell.](https://reader036.fdocuments.net/reader036/viewer/2022062421/56649d835503460f94a68fae/html5/thumbnails/28.jpg)
CHD1CHD1SAGASAGA
HAT complexHAT complex
Hum H3 n-ARTHum H3 n-ARTKKQTARQTARKKSTGGSTGGKK……44 99
K4K4 K9K9K4K41,2me1,2me
K4K43me3me
Ash1, Rtf1,Trr, Trx?Ash1, Rtf1,Trr, Trx?
Su(var)3-3?Su(var)3-3?
Lid/JARID1CLid/JARID1C
K9K9acac
K9K9meme
HATs,CBPHATs,CBP
Ash1,Egg,G9a,
Ash1,Egg,G9a,Su(var)3-9
Su(var)3-9??
Cg8165,15835,33182?
Cg8165,15835,33182?
Sin3A,Rpd3, Sir2
Sin3A,Rpd3, Sir2
MeMeMeMe
HP1HP1
Factor bindingFactor bindingActivationActivation
Transcription is regulated by modifying histones.Transcription is regulated by modifying histones.H3K4;9 – a control node for therapeutic intervention in HD?H3K4;9 – a control node for therapeutic intervention in HD?
Phot
orep
tors
Phot
orep
tors
5.05.0
5.45.4
5.85.8
6.26.2
6.66.6
7.07.0
CyOCyO Sin3A+/-Sin3A+/-
Surv
ival
Surv
ival
002020404060608080100100
TM3TM3 SUV39+/-SUV39+/-
AcAcAcAc
00
2020
4040
6060
8080
lid+/-lid+/- CyOCyO
% e
xpec
ted
% e
xpec
ted
Phot
orep
tors
Phot
orep
tors
5.05.0
5.45.4
5.85.8
6.26.2
6.66.6
7.07.0
CyOCyO Sin3A+/-Sin3A+/-
1414